Safety and Immunogenicity of CVI-VZV-001 for Prevention of Herpes Zoster in Healthy Adults Age 50 Years and Above
Safety and Immunogenicity of CVI-VZV-001 for Prevention of Herpes Zoster in Healthy Adults Age 50 Years and Above
Recruiting · NCT06137755 · Registry updated 2024-11-19Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety and Immunogenicity of CVI-VZV-001 for Prevention of Herpes Zoster in Healthy Adults Age 50 Years and Above | DNA Virus Infections, Herpesviridae infectious disease, Infections, Vaccine-Preventable Diseases, Varicella Zoster Virus Infection, herpes zoster, viral infectious disease | Recruiting | Phase 1 | 2024-11-19 | NCT06137755 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Aribio Lab Co., Ltd. | 2 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Bundang CHA General Hospital | Seongnam-si | South Korea | 1 |
| The Catholic University of Korea, Eunpyeong St. Mary's Hospital | Seoul | South Korea | 6 |